Helperby Therapeutics Group

Helperby Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing a new class of drugs called Antibiotic Resistance Breakers (ARBs). The company's platform focuses on discovering compounds that, when combined with existing antibiotics, restore their efficacy against multi-drug resistant (MDR) bacteria. By targeting non-multiplying 'persister' bacteria and permeabilizing the bacterial cell wall, Helperby aims to extend the life of current antibiotic classes and combat the global threat of antimicrobial resistance. Their pipeline includes treatments for MRSA, complicated urinary tract infections, and respiratory infections in cystic fibrosis patients. This approach provides a faster and more cost-effective route to market compared to developing entirely new classes of antibiotics.